A SAFETY AND EFFICACY OF COMBINATION THERAPY OF DEFERASIROX AND DEFEROXAMINE VERSUS DEFERASIROX FOR TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN SICKLE CELL ANEMIA IN AL-NAJAF AND BABYLON PROVINCE IN IRAQ

Abstract

oai:oai.medrech.com:article/1Background:- In Sickle cell anemia, transfusions improve blood flow by reducing the proportion of red cells capable of forming sickle hemoglobin polymer. This limits hemolysis and endothelial damage and repeated blood transfusion leading to iron overload or transfusion hemosiderosis, the only way to prevent this are by long-term chelation therapy. Objectives: - The aim of this study is to assess the efficacy and safety of combination therapy in a group of patients with sickle cell anemia. Patients and method:- The prospective study was done on sixty-five patients with the sickle cell anemia, conducted to Al-Najaf and Babylon thalassemia centers, classify into two groups, those on combined therapy of Deferoxamine-Deferasirox treatment as the second group, while on Deferasirox alone as the first group and its aim to assess the safety of the combined treatment. Results: - Both regimens proved to have less adverse effects on hepatic or renal function and pellet count. The degree of reduction of serum ferritin is significantly higher with combined Deferoxamine-Deferasirox therapy. Conclusion: - combined chelating agents have a significant effect on serum ferritin, with an acceptable level of safety